echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Immunology News > GSK AIDS new drug Dotiravelpivelin tablets are listed in the domestic newspaper

    GSK AIDS new drug Dotiravelpivelin tablets are listed in the domestic newspaper

    • Last Update: 2021-01-21
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    On January 8, CDE's official website announced that GSK/ViiV's application for the listing of the new imported drug "Dotiravelpivelin Tablets" had been accepted.
    the drug is a new HIV-2 compound drug.
    HIV is a severe autoimmune disease caused by retrovirus HIV, which has become a major global public health problem since it was first discovered in 1981.
    , however, the disease is still not completely eradicated and patients need to take medication for life.
    current anti-HIV drugs mainly include CCR5 antagonists, fusion inhibitors, reverse transcriptase inhibitors, integrated enzyme inhibitors, protease inhibitors.
    in order to avoid drug resistance from a single drug, most of the above three or more drugs are used clinically in a combined way.
    HIV drugs, which are among the top 100 drugs in global drug sales in 2019, include Gilead and have five Top100 HIV drugs: Biktarvy (Bikhnprono), Genvoya (Ekonpropan), Truvada (Entouritham/Tenofwe), Odefsey and Descovy.
    Johnson and Johnson and GSK each own 1/2 models, Prezista/Prezcobix (Da lunawe/Trinaway) and Tivicay (Dotirawe) and Triumeq (Dote Ablamy, Dotilawe / Ramifding / Abakawe).
    , in general, the two-link and three-link complex is the main.
    the newspaper's listed Dotera velipivirin tablet is a new two-in-one HIV compound, consisting of dolutegravir and rilpivirine in 50mg/25mg sizes.
    among them, dotiravir (DTG) belongs to the integrated enzyme chain transfer inhibitor (INSTIs), which blocks HIV from integrating viral DNA into the host CD4 cells, and Lipivirin (RPV) belongs to a non-nucleoside retrovirase inhibitor (NNRTIs), which inhibits HIV-1 retrovirusase and thus inhibits viral replication.
    Dotiravelpivirin is a long-term maintenance therapy drug for HIV-1 adults who have received at least 6 months of stable antiretroviral programs to achieve virological inhibition (HIV-1RNA-lt;50 copies/ml) and have no history of virological failure, while no known or suspected drug-resistant mutations in NNRTI or INSTI.
    november 2017, the drug was approved for market by the FDA.
    2019 global sales of $468 million, according to the Insight database.
    At present, the country has also approved a number of HIV compound preparations, of which the secondary compound preparations include ViiV health care Abacaveramiv tablets, Gilead's entourta binofowe tablets and enturabin propofol tablets, Belgium Jansen's Daruna Vecobista tablets, GlaxoSmithKline's Zidorami duff tablets and so on.
    , however, the domestic HIV new drugs are still mainly imported, Insight database shows that the current AIDS indications containing new drugs, 38 items for imports, only 10 items for domestic varieties.
    of the domestic varieties, only Frontier Bio's Abbot Weitai has been approved for listing, while Real Creatures' Azvdin and Eddie Pharmaceuticals ACC007 have submitted applications for listing, with the rest at the clinical stage.
    from insight database ()
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.